Management of Symptomatic BPH in the UK: Who Is Treated and How?

Publisher Website
Google Scholar
Abstract
Objective: To review the contemporary management of symptomatic benign prostatic hyperplasia (BPH) in the United Kingdom (UK). Methods: Information was obtained from published scientific articles, IMS market analysis data and surveys among primary care practitioners and urologists. Results: A survey in Stirling (Scotland) identified the number of men aged 40–79 years with symptomatic BPH defined as a prostate size >20 g with urinary symptoms (total symptom score ≧11) and/or a maximum urinary flow rate 1-adrenoceptor antagonists have increased steadily during the latter part of the 1990s whereas that for finasteride has remained flat. In 1998, α1-adrenoceptor antagonists had 64% market share and finasteride 36% from a total market of 53 million Euro. Conclusions: In the UK, challenges for the future management of symptomatic BPH will be the increased number of patients, further enhancement of efficient co-operation between PCGs and urologists and evaluation of most appropriate management of this condition from a disease progression and cost-effectiveness point of view.

This publication has 0 references indexed in Scilit: